Navigation Links
New Drug Offers Promise as Single Treatment for HIV

An experimental antiretroviral drug designated "MK-0518" rapidly achieves sharp reductions in human immunodeficiency virus (HIV) levels, and may offer the prospect of single-//drug treatment for patients with HIV infection.

If the good results are borne out by further studies, "MK-0518 should clearly be a welcome addition to the existing treatment options for those persons infected with HIV-1," concludes the new study, led by Dr Martin Markowitz of The Rockefeller University, New York.

Thirty-five previously untreated patients with HIV infection were randomly assigned to receive one of four different doses of MK-0518, or to receive an inactive placebo. After 10 days of treatment, the patients' "viral load" was measured. The viral load is a key test that determines how well HIV—the virus that causes AIDS—is reproducing in the patient's body. At the start of the study, all patients had a relatively high viral load of 5,000 copies per milliliter of blood.

Patients taking MK-0518 had dramatic reductions in their viral load. After just 10 days of treatment, viral load decreased by an average of 98 percent (based on the logarithmic scale used to measure HIV levels).

The results were similar across all four MK-0518 dose groups. For most patients in each group, the viral load dropped to an "undetectable" level of less than 400 copies per milliliter.

Treatment with MK-0518 was "generally well tolerated," the authors write. Side effects such as headache and dizziness occurred, but there were no major adverse effects.

Although major advances have been made in drug treatment of HIV, new treatments are still needed for several reasons. Current approaches require complex combinations of drugs, with many short- and long-term toxic effects. Drug resistance is also an increasing problem, as new strains of HIV become resistant to the effects of current antiretroviral drugs.

There is special interest i n MK-0518 because it works in a different way than other anti-HIV drugs. Previous antiretroviral drugs target enzymes called reverse transcriptase and protease, which play key roles in the virus' ability to reproduce itself.

MK-0518 targets a "third enzyme" called integrase, which is found only in HIV and is essential to the virus' ability to insert its DNA into human genes. By blocking integrase, MK-0518 blocks HIV's ability to reproduce itself and infect new cells. Because it works differently, MK-0518 should also reduce interactions with other anti-HIV drugs.

Although preliminary, the study suggests that MK-0518 is a potent, well-tolerated single-drug treatment that is highly effective in reducing HIV viral loads, the investigators conclude. Based on the successful results, a second phase of the study—comparing various doses of MK-0518 with current combinations of anti-HIV drugs—is already underway.

Source-Newswise
RM
'"/>




Related medicine news :

1. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
2. Drug Offers Hope for Alzheimers disease
3. Drug Firm Offers to Donate Smallpox Vaccine
4. fMRI Offers Insight Into An Infants Brain
5. Gel Offers A More Targeted Approach
6. Umbilical Cord Blood Offers Hope For Patients Who Require Bone Marrow Transplants
7. Surgery Offers Better Treatment For Third Degree Piles
8. New Study Offers Hope For Balding Men
9. Gamma Knife Offers New Hope For Trigeminal Neuralgia Patients
10. Study Offers Insights Into Treatment Of Rheumatoid Arthritis
11. CPHA Offers HIV Information Packages To Canadian Football League Teams
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as ... production of the series is on hiking in American. Viewers can reconnect with America ... great benefits of hiking. , Many consumers have looked for an inventive new place ...
(Date:5/26/2017)... ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of ... Cross” is the creation of published authors, Bob and Margaret Massey. Bob Massey is ... is "panther quick and leather tough." His love for others is apparent in all ...
(Date:5/26/2017)... ... ... Jack: Against All Odds”: the story of Coach Cactus Jack and the impact he ... creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist and pharmacy ... Walter and Jane have three adult children and a granddaughter. Walter and ...
(Date:5/24/2017)... ... May 24, 2017 , ... In ... choosing the most appropriate instruments for research and understanding the basic principles that ... webinar will focus on innovations in stereo microscopy for brightfield and fluorescence typically ...
(Date:5/24/2017)... California (PRWEB) , ... May 24, 2017 , ... ... through innovative medical image management and interpretation, has received U.S. Food and Drug ... , Nucleus.io is a web-based, scalable and secure cloud platform for medical image ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading healthcare data analytics ... 2017 ranking of the Best-Equipped Hospitals in Latin America ... GHI,s hospitals database for Latin America , which is ... database covers 86% of the hospitals in Latin ... each institution in key areas such as beds, medical specialties, ...
(Date:5/9/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... has earned a spot on Forbes, "America,s ... ranked among 500 U.S. employers as well as in ... Services. The annual Forbes rankings ... of over 30,000 employees across 25 industries. The survey ...
Breaking Medicine Technology: